The pilot bioavailability study comparing the absorption of carbetocin (which is used as prevention of heavy bleeding after childbirth) in PABAL 100 μg/mL Solution for Injection when administered sublingually in the dose of 500 μg and intramuscularly in the dose of 100 μg.

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524768-39-00

Enrollment

Registered

2026-02-09

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Not applicable (submitted trial is a bioavalability study in healthy participants).

None listed

Sex/Gender

All

Age

18 Years to 64 Years

None listed

Source: EU CTIS · Data processed: Feb 10, 2026